Roth Capital Downgrades Pharmacyclics (PCYC) to Neutral
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 46 | New: 42
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 46 | New: 42
Join SI Premium – FREE
Roth Capital downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral with a price target of $57.00.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $62.89 yesterday.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $62.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral
- Freedom Broker Downgrades Dorman Products (DORM) to Hold
- Cantor Fitzgerald Downgrades monday.com Ltd. (MNDY) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
